Brak połączenia z internetem — wyświetlanie zapisanej wersji strony.

Molecular Partner…

CHCHF
← Do Screenera

Molecular Partners AG (LSE:0QXX) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 3. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.

O Firmie

Strona
molecularpartners.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siedziba
Schlieren-Zurich, Switzerland
Prezes
Patrick Amstutz
Pracownicy
134
Akcje w Obrocie
38.31 mln
Free Float
20.71 mln
Kapitalizacja Rynkowa
127.56 mln CHF
Insiderzy
8.47%
Inwestorzy Instytucjonalni
43.8%
Branża (SIC)
Biological Products, (No Diagnostic Substances)
Forma Prawna
MVII
ISIN
US60853G1067
LEI
875500AXMLDAZ4D21744
FCF
−52.0 mln CHF
Dług
?
Zyski i FCF — za 12 miesięcy do 31.12.2025 roku (najnowszy raport firmy).
Opis

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

reklama

Giełdy i Tickery

GiełdaTickerWalutaCenaTyp
SW SIX Swiss ExchangeMOLN główneCHF3.33 -0.30%akcje zwykłe
LSE London Stock Exchange0QXX IOBCHF3.39 +0.00%akcje zwykłe
US USA StocksMLLCF OTCUSD4.01 +0.00%akcje zwykłe

Cena z 3 Miesięcy

dzień wzrostu dzień spadkuNajedź / dotknij dnia — ceny otwarcia, zamknięcia, najwyższa i najniższa

Najwięksi Akcjonariusze

PosiadaczUdziałAkcjeData Raportu
Old Mission Capital, LLC0.03%11 3472025-06-30
DFA INVESTMENT DIMENSION…0.01%3 9232026-07-31
DFA INVESTMENT DIMENSION…0.01%3 5032026-07-31
American Century ETF Tru…0%122026-08-31